Basics CRISPR Therapeutics AG CRISPR Therapeutics AG is a gene editing company. It is engaged in the development of CRISPR/Cas9-based therapeutics. IPO Date: October 19, 2016 Sector: Healthcare Industry: Biotech Market Cap: $3.64B Activated in VL: True Average Daily Range Avg Daily Range: $1.62 | 2.80% Avg Daily Range (30 D): $0.88 | 2.30% Avg Daily Range (90 D): $1.12 | 2.87% Institutional Daily Volume Avg Daily Volume: 1.12M Avg Daily Volume (30 D): 2.06M Avg Daily Volume (90 D): 2.06M Trade Size Avg Trade Size (Sh.): 64 Avg Trade Size (Sh.) (30 D): 60 Avg Trade Size (Sh.) (90 D): 64 Institutional Trades Total Inst.Trades: 5,301 Avg Inst. Trade: $2.72M Avg Inst. Trade (30 D): $2.41M Avg Inst. Trade (90 D): $2.31M Avg Inst. Trade Volume: .04M Avg Inst. Trades (Per Day): 3 Market Closing Trades Avg Closing Trade: $4.87M Avg Closing Trade (30 D): $4.67M Avg Closing Trade (90 D): $5.23M Avg Closing Volume: 73.96K     News Jun 3, 2025 @ 8:30 AM The Best Stocks to Invest $1,000 in Right Now Source: James Brumley May 20, 2025 @ 8:30 AM 5 Monster Stocks to Hold for the Next 10 Years Source: Justin Pope May 18, 2025 @ 1:30 PM Prediction: This Beaten-Down Stock Could Double in... Source: Prosper Junior Bakiny May 16, 2025 @ 3:37 PM CRISPR Therapeutics Stock Near 5-Year Lows—... Source: Marketbeat.Com May 13, 2025 @ 11:10 AM 2 Biotech Stocks That Are Screaming Buys in May Source: Adria Cimino Financials   TTM Q1 2025 Q4 2024 Basic EPS $-4.5 $-1.58 $-.42 Diluted EPS $-4.5 $-1.58 $-.42 Revenue $ 37.68M $ .87M $ 35.69M Gross Profit $ $ $ Net Income / Loss $ -385.66M $ -136M $ -37.31M Operating Income / Loss $ -474.4M $ -148.42M $ -64.59M Cost of Revenue $ $ $ Net Cash Flow $ -472.27M $ -63.11M $ 72.67M PE Ratio